Pennington Biomedical researchers report that the triple agonist retatrutide produced 25% to 30% weight loss in phase 3 trials, comparable to bariatric surgery and the largest seen in its class. The findings also catalog unexpected benefits of GLP-1 drugs, including reduced alcohol craving,…
Pennington Biomedical Research Center researchers are reporting that retatrutide , an experimental triple agonist combining GLP-1, GIP, and glucagon activity, has produced 25% to 30% weight loss in phase 3 trials, a result comparable to bariatric surgery and the most seen so far in this class of drugs. The same body of work, delivered by Dr. Steven Heymsfield, professor at Pennington Biomedical and director of the Metabolism Body Composition Laboratory, catalogs newly appreciated benefits beyond weight loss and newly recognized harms that clinicians are only beginning to manage.
Heymsfield has studied GLP-1 drugs for 15 years. For about 5 of those years, the drugs have been used for weight loss in clinical practice. That split matters. The molecules were developed and approved as diabetes treatments, and their repurposing as weight-loss agents has been rapid enough that the full range of effects, beneficial and harmful, is still being mapped.
What has emerged, Heymsfield said, is a mixture of the predicted and the unforeseen. "Some were predicted beforehand and others were completely surprising."
Retatrutide is not yet on the market. It is in phase 3 trials, the last phase before approval, and could reach the market within the next few years. Approval timelines for this class have been moving faster recently; 2 oral GLP-1 drugs have already come to market quickly, and a triple agonist producing weight loss comparable to bariatric surgery would raise the commercial stakes further.
Some benefits were predicted before the drugs entered wide use. People with obesity have a higher risk of diabetes, so improvements in metabolic health were expected. Other effects were not.
"The unpredictable type is that people report less desire to drink alcohol," Heymsfield said.
Studies have confirmed that people on GLP-1 drugs report a reduced desire to drink alcohol. Researchers believe GLP-1s may act on brain areas tied to alcohol and substance use behaviors, which would explain why a drug designed to regulate blood sugar and food intake also changes drinking behavior.
Similar reports have accumulated for arthritis. People with arthritis on GLP-1 drugs report improved symptoms, less pain and inflammation, and better walking ability. Studies show GLP-1 users need fewer knee replacements. These findings go beyond what joint unloading from weight loss alone would predict, which is one reason researchers now suspect a direct anti-inflammatory effect.
The cardiovascular data are the most consequential. "We've already shown with GLP-1s that it reduced the risks of heart attacks, cardiovascular disease, mortality," Heymsfield said. The mechanism may be independent of weight loss. "It looks like it's not just the weight loss, but these drugs that actually have themselves some properties that improve inflammation."
That anti-inflammatory signal is strong enough that GLP-1 drugs are likely being prescribed off-label to treat inflammation, including in people of normal weight. Off-label prescribing carries risk because the effects of the drugs in non-approved populations are unknown, and the dose, duration, and safety profile established in obesity and diabetes trials cannot be assumed to transfer.
The same reports that expanded the benefit profile have also expanded the list of adverse effects. Some patients on GLP-1 drugs develop vitamin deficiencies, including scurvy from vitamin C deficiency. Others experience hedonia , a loss of enjoyment of eating, and some stop treatment because of it.
Hedonia sits at the opposite end of the spectrum from food noise , the persistent intrusive thoughts about food that many patients report disappearing on GLP-1 therapy. Reduced food noise is generally beneficial, but in some patients the effect becomes too pronounced and eating becomes joyless. Managing that balance, keeping the reduction without crossing into hedonia, is a clinical problem with no established protocol.
Muscle and bone loss occur in everyone who loses weight on GLP-1 drugs. The loss is more problematic for frail patients, such as a 75-year-old overweight person starting a GLP-1, where reduced muscle mass could worsen mobility and increase fracture risk. Pennington researchers are studying increased protein intake, resistance exercise, and androgen-type drugs as candidate strategies to prevent muscle loss during treatment.
The drugs are safe when taken as prescribed, with well-described gastrointestinal effects and low overall risk, particularly at lower doses. The risk profile changes with potency. Retatrutide was associated with more side effects than existing GLP-1 drugs, and weight loss that approaches surgical results may carry a proportional increase in adverse effects.
The retatrutide results come from phase 3 clinical trials, the controlled studies that generate the efficacy and safety data required for approval. The trials measured weight loss as the primary endpoint and tracked side effects as part of the safety assessment.
What the phase 3 evidence establishes is efficacy. A 25% to 30% average weight loss places retatrutide in a range previously achieved only by bariatric surgery, and it does so with a peptide rather than an operation. What the evidence does not establish, at least not in the information currently available, is the full safety picture. The trial population, sample size, and duration are not part of the reporting, which means the side-effect signal cannot be quantified or compared with existing drugs in a rigorous way.
The design also cannot separate the contributions of the three receptor activities to the outcome. The weight-loss figure is a compound result, and answering which component drives efficacy, and which drives the extra side effects, will require dedicated studies.
Retatrutide activates three receptors simultaneously. GLP-1 receptor activation stimulates insulin secretion in response to meals, slows gastric emptying, and acts on appetite centers in the brain. GIP, the glucose-dependent insulinotropic polypeptide, amplifies the incretin response and supports insulin sensitivity. Glucagon receptor activation increases energy expenditure. The logic of the triple agonist is to attack obesity through multiple routes at once: less food intake, better insulin handling, and more calories burned.
That pharmacology helps explain the size of the effect. Combining three receptor activities produces more weight loss than the single-receptor GLP-1 drugs that defined the class, and the 25% to 30% figure is the largest reported so far. The same broad receptor distribution helps explain the heavier side-effect burden. Activating three metabolic pathways amplifies the intended effects and the unintended ones.
The brain effects are the least understood. Researchers believe GLP-1s may act on brain areas tied to alcohol and substance use behaviors, and the clinical reports of reduced drinking are consistent with that hypothesis. The reward circuits that govern appetite overlap with those that govern craving, which may explain why a drug that suppresses food intake also suppresses the desire for alcohol.
The anti-inflammatory effects are equally intriguing. Arthritis symptom improvement, fewer knee replacements, and cardiovascular risk reduction that appears out of proportion to weight loss all point in the same direction. The mechanism of that anti-inflammatory action has not been established, and separating it from the metabolic effects of weight loss is an active research problem. The muscle and bone loss seen in all patients who lose weight on these drugs is the flip side of the same coin: potent metabolic signaling changes body composition in ways that are not all beneficial.
The Peptide Atlas trial registry for retatrutide, developed under the code LY3437943 , lists 33 registered clinical trials on file. The phase breakdown shows a program concentrated at the late stage: 6 phase 3 trials, 3 phase 1 trials, and 1 phase 2 trial. Trial status records show 4 recruiting, 4 active, and 2 completed.
The registered trials map the intended clinical scope. NCT07467447 is a phase 2 trial of LY3437943 versus placebo in participants who have obesity or are overweight. NCT07357415 and NCT07232719 are active phase 3 trials in participants without type 2 diabetes who have obesity or overweight. NCT07035093 is a phase 3 trial in participants who have obesity or overweight and chronic low back pain, a direct extension of the pain and arthritis signals in the clinical literature. NCT07165028, a phase 3 master protocol in adults with metabolic dysfunction-associated steatotic liver disease, tests the drug against a second major metabolic condition. NCT06982859, a phase 1 trial, examines the effect of retatrutide on insulin secretion and insulin sensitivity in adults with type 2 diabetes.
The literature base is still small but growing. Peptide Atlas indexes 71 PubMed papers on retatrutide. Recent additions include TRANSCEND-T2D-1, a double-blind, randomized phase 3 trial in people with type 2 diabetes and inadequate glycemic control, published in the Lancet in June 2026 PMID 42250575 , and a systematic review and meta-analysis of randomized controlled trials on the drug's effects on blood pressure and lipid levels PMID 42371360 . A second meta-analysis covers the effect of incretin-based therapies on blood pressure PMID 40899050 . Preclinical work includes a study of retatrutide's effects on learning and memory in diabetic rats, published in Behavioural Brain Research PMID 42385950 , and a synthesis paper describing a hydrophobic tag-assisted liquid-phase strategy for producing the peptide PMID 42224238 .
Supply-side data on file are limited but clean. Peptide Atlas records 18 third-party laboratory purity tests for retatrutide, with a highest observed purity of 99.908%. For a peptide this complex, purity at that level matters because the synthesis itself is a challenge and impurities can carry their own pharmacology. Eighteen tests is a small sample for a drug entering late-stage trials, and purity documentation should be treated as a per-batch question rather than a settled one.
For clinicians, the immediate task is monitoring. Vitamin status, particularly vitamin C, should be on the radar for patients on long-term GLP-1 therapy, along with functional assessments of strength and mobility in older patients. The 75-year-old frail patient example is not hypothetical: weight loss in that population is double-edged, reducing metabolic risk while accelerating sarcopenia and fracture risk. Protein intake and resistance exercise are the available countermeasures, and the interest in androgen-type drugs reflects a search for a pharmacological way to preserve lean mass while fat is lost.
For researchers, the open mechanism questions define the next wave of studies. The alcohol craving signal suggests GLP-1 receptor signaling modulates reward circuitry in ways that could extend to substance use disorders. The anti-inflammatory effects, if confirmed to be independent of weight loss, would position these peptides as a new class of anti-inflammatory agents. The distinction matters for off-label use. If the cardiovascular benefit is largely anti-inflammatory, normal-weight patients with inflammation might benefit, but no trial data support that use, and the risk of unexpected effects in that population is real.
For the peptide supply chain, retatrutide represents a manufacturing step up. The molecule combines three receptor activities in one sequence, and the synthesis is demanding enough that chemistry papers on how to make it are still being published. The high observed purity in third-party tests, 99.908%, is encouraging, but it reflects 18 tests on…
Peptides referenced: Retatrutide, Glucagon, GLP-1.
Related reading: GLP-1 therapies show cardiovascular benefit beyond glucose control, Survey: 44% of sports medicine physicians would prohibit GLP-1 drugs, Imperial Peptides UK sets MT-2 documentation standard for research supply, Handling Guide for Lyophilised MT-2: Identity, Storage, Traceability.